Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma Post author: Post published:March 1, 2026 Post category: Continue ReadingIntracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) Post author: Post published:March 1, 2026 Post category: Continue ReadingT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme Post author: Post published:March 1, 2026 Post category: Continue ReadingB7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Treatment of Moderate to Severe Refractory Crohn’s Disease Post author: Post published:March 1, 2026 Post category: Continue ReadingTreatment of Moderate to Severe Refractory Crohn’s Disease
SUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma Post author: Post published:March 1, 2026 Post category: Continue ReadingSUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis Post author: Post published:March 1, 2026 Post category: Continue ReadingSafety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer Post author: Post published:March 1, 2026 Post category: Continue ReadingA2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
CAR-T Cells for HIV Infection Post author: Post published:March 1, 2026 Post category: Continue ReadingCAR-T Cells for HIV Infection
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Post author: Post published:March 1, 2026 Post category: Continue ReadingIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
